Corvus Pharmaceuticals (CRVS)

• Market cap: $1.47B
• 1 day: -2.01%
• 5 days: -1.63%
• 1 month: -17.85%
• 3 months: 107.7%
• 6 months: 211.92%
• Year to date: 139.48%
• 1 year: 343.8%
• 5 years: 453%
• 10 years: 23.02%
• Sector: Healthcare
• Industry: Biotechnology

About: Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Employees: 31